Petrelintide dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Petrelintide is a once a week shot from Zealand and Roche that copies amylin, a fullness hormone. It is being made as a gentler weight loss drug. A mid-stage study found up to about 11 percent weight loss.
Evidence grade for Petrelintide: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 1 completed trial, 493 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 493
- Human studies
- 1
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
1 completed trial, 493 people given it
2 effects reported, 1 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Petrelintide is a once a week shot from Zealand and Roche. It copies amylin, a hormone that makes you feel full. The hope is that it is easier on the stomach than Ozempic and its cousins. It is not approved.
What people take it for
- Weight loss with less nausea.
- Something to pair with a GLP-1 drug later.
What studies in people showed
In a mid-stage study of 493 people, the company says people lost up to 10.7 percent of their weight in 42 weeks. People on a dummy shot lost 1.7 percent. That came from a press release, so no outside expert has checked it yet. In the first studies in people, side effects were mostly mild stomach trouble. A large final-stage study is planned for late 2026.
What people report
Reports, not study results
The good
- In the studies on this page, people lost weight, and early side effects were mostly mild.
The bad
- Mild stomach trouble was the main side effect in the first studies on this page.
Where these come from: Both lines are from the studies and the company release on this page. We have not collected forum or user reports for this drug yet.
My bottom line
Gentler may matter to people who cannot handle the GLP-1 drugs. But it takes off less weight so far. It is not approved, so there is nothing real to buy.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Petrelintide has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weight493 people · 2 studies
35 of the 36 indexed goals have no study of any kind behind Petrelintide
No study in people, animals or cells on this page reports a result for these. That does not prove Petrelintide does nothing for them. It does mean anything you have heard about Petrelintide and one of these did not come from a study cited here.
Show full evidence
What is Petrelintide?
Petrelintide is a once a week shot from Zealand and Roche that copies amylin, a fullness hormone. It is being made as a gentler weight loss drug. A mid-stage study found up to about 11 percent weight loss.
Petrelintide is an experimental once a week shot from Zealand Pharma and Roche. It copies amylin, a hormone that makes you feel full. The idea is that amylin drugs may be easier on the stomach than GLP-1 drugs like Ozempic. In a mid-stage study called ZUPREME-1, with 493 people, the company reports up to 10.7 percent average weight loss after 42 weeks. People on a dummy shot lost 1.7 percent. A large final-stage study is planned for the second half of 2026. It is not approved.
How does Petrelintide work?
It turns on the amylin signal. That makes you feel full sooner and slows how fast food leaves the stomach. It is used on its own, not mixed with another drug.
The evidence, in charts
Fig. 1a · how many people
493people, across 1 study in people cited here
| Study | People | Share |
|---|---|---|
| ZUPREME-1, Zealand Pharma press release 2026 | 493 | 100% |
The whole total is one study of 493. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
2 of 3 sources here are studies in people. The rest is not.
- Study in people · done in people267%
- Animal study · done in animals133%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2025 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- 4,192 Da
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for Petrelintide, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2026Safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide for weight management: two randomized, controlled phase 1 trials
The earliest human studies went smoothly and showed weight coming off. Side effects were mostly mild stomach trouble. The purpose of trials at this stage is to find out whether people can take a drug at all, and at what dose. This one passed that test, which is why it went forward. It is not evidence that the drug works.
Well tolerated with mostly mild GI events and clinically relevant weight loss; supports development for weight management.
- Study in people2026Zealand Pharma announces positive Phase 2 results for petrelintide (ZUPREME-1)
It works, and it works less well than the drugs it is chasing. 493 people took part, and the company reports up to about 11 percent average weight loss after 42 weeks, against under 2 percent on a dummy. This is a press release, so no outside reviewer has been through the detail yet. A larger trial is meant to start later in 2026.
March 5, 2026: 493 participants; up to 10.7% mean weight loss at 42 weeks versus 1.7% with placebo; Phase 3 to start later in 2026.
- Animal study2025Development of petrelintide: a potent, stable, long-acting human amylin analogue
In the lab, chemists built this drug as a stable, long-lasting copy of human amylin, so it could be given once a week. This paper is about how it was made. Nobody took it in this paper.
Medicinal chemistry paper describing the design of petrelintide as a stable, long-acting human amylin analogue for weekly dosing.
Where to buy Petrelintide
No seller we track lists Petrelintide yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Petrelintide been tested in people?
Yes. 493 people given it across 1 completed trial cited here, 0 of which found nothing. Petrelintide is a once a week shot from Zealand and Roche that copies amylin, a fullness hormone. It is being made as a gentler weight loss drug. A mid-stage study found up to about 11 percent weight loss.
What is the Petrelintide dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 1 completed trial, 493 people given it
Is Petrelintide FDA-approved?
Investigational (final-stage studies are planned to start in the second half of 2026)
Why develop an amylin-only drug?
Amylin drugs like petrelintide may cause less nausea than GLP-1 drugs. So they are being tested alone and with other drugs, to see if people handle them better.
Latest reading on Petrelintide
Blog posts about Petrelintide, newest first.